Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Green Cross claims hypolipidemic agents

March 12, 1997

Recombinant human hemoglobin produced by transgenic tobacco

March 11, 1997

Millennium obesity gene patent application receives U.S. notice of allowance

March 10, 1997

Axcan signs distribution agreements for Protectaid

March 10, 1997

AY-4166: preclinical toxicity and pharmacokinetics studies

March 10, 1997

Synaptic receives patent for "feeding" gene

March 7, 1997

Licensees/CRADA partners sought for antiprogestins

March 7, 1997

Bayer initiates international diabetes prevention project

March 6, 1997

Allelix reports progress in osteoporosis trial

March 6, 1997

Novel post-Amadori inhibitors identified

March 5, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.